The chronic kidney disease (CKD) treatment market is experiencing robust growth across the 7MM, driven by rising disease prevalence, aging populations, increasing cases of diabetes and hypertension, and the emergence of innovative therapies from leading companies including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others.
Chronic Kidney Disease Market Insights, Epidemiology, and Forecast
DelveInsight’s “Chronic Kidney Disease Market Insight, Epidemiology, and Market Forecast – 2034” provides comprehensive insights into CKD, covering historical and forecasted epidemiology, current treatment paradigms, and emerging therapies across the 7MM (United States, EU4, United Kingdom, and Japan).
The 7MM CKD market was valued at approximately USD 4.6 billion in 2023 and is projected to grow steadily through 2034. The United States is the largest contributor, representing nearly USD 2.5 billion, significantly outpacing the EU4, UK, and Japan. Within Europe, Germany leads and is expected to maintain dominance through 2034, followed by the UK, while Japan also holds a substantial share. Market growth is driven by increasing prevalence, improved diagnostics, and the adoption of advanced therapies.
Download the chronic kidney disease market report to understand which factors are driving the CKD therapeutic market @ Chronic Kidney Disease Market Trends.
Epidemiology and Patient Segmentation
DelveInsight estimates that nearly 82 million individuals were diagnosed with CKD across the 7MM in 2023, with numbers expected to rise significantly over the next decade. The US accounted for the highest diagnosed prevalent cases (~4 million), with stage 3 CKD representing the largest patient segment.
Gender disparities are evident, with women showing higher prevalence in early stages. Age-specific data indicates the highest prevalence among individuals aged 65 and older, highlighting the need for age- and gender-specific management strategies.
Diabetes and hypertension remain primary CKD drivers, with prevalence increasing markedly with age. Recognition of non-traditional risk factors such as obesity, environmental exposures, and certain medications is reshaping CKD epidemiology.
Treatment Landscape and Emerging Therapies
The CKD therapeutics landscape has evolved from focusing solely on slowing disease progression to targeting specific pathways. SGLT2 inhibitors such as FARXIGA (dapagliflozin) and INVOKANA (canagliflozin) demonstrate renoprotective benefits beyond glycemic control, reducing risks of kidney failure and cardiovascular events. KERENDIA (finerenone), a non-steroidal mineralocorticoid receptor antagonist, further expands options by addressing inflammation and fibrosis in diabetic kidney disease.
Renal anemia treatments have advanced with HIF-PH inhibitors like VAFSEO (Akebia Therapeutics) and EVRENZO (Astellas), offering oral alternatives to traditional erythropoiesis-stimulating agents and potentially lower cardiovascular risks. KORSUVA (Cara Therapeutics) addresses CKD-associated pruritus (CKD-aP), improving quality of life for hemodialysis patients.
The CKD pipeline is robust, featuring candidates targeting multiple aspects of disease progression: Ocedurenone (KBP Biosciences) for resistant hypertension; Sparsentan (Travere Therapeutics) for IgA nephropathy and FSGS; and atrasentan (Chinook Therapeutics) for proteinuric kidney diseases. Cell and gene therapies, such as FCR001 (Talaris Therapeutics) for transplant tolerance, and bispecific antibodies targeting inflammatory pathways are also advancing.
Unlock which chronic kidney disease emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Chronic Kidney Disease Market Insights.
Recent Developments
Key regulatory milestones in early 2025 have expanded treatment options:
- March 2025: FDA approval of Furoscix (furosemide injection, scPharmaceuticals) for edema in adult CKD patients, including nephrotic syndrome, with availability expected by April 2025.
- January 2025: Semaglutide (Novo Nordisk) approved for reducing risk of worsening CKD, kidney failure, and cardiovascular death in adults with type 2 diabetes.
- November 2024: FDA accepted Unicycive Therapeutics’ NDA for Oxylanthanum Carbonate (OLC) for hyperphosphatemia in dialysis patients, with a PDUFA date of June 28, 2025.
These developments underscore a rapidly evolving CKD market, providing improved outcomes for patients.
Discover evolving trends in the chronic kidney disease treatment landscape @ Chronic Kidney Disease Recent Developments.
Market Challenges and Future Outlook
Despite advancements, challenges remain, including delayed diagnosis, complex multifactorial disease mechanisms, polypharmacy concerns, and economic burden. DelveInsight emphasizes the need for biomarker-driven, personalized treatments and early intervention strategies.
Looking ahead, the CKD market is poised for transformation, with late-stage therapies expected to gain approval and combination regimens likely becoming standard. Integration of artificial intelligence in predictive modeling and treatment selection promises to enhance personalized care, enabling earlier interventions in high-risk populations and optimizing therapy based on patient characteristics and CKD subtypes.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting
